Elevated serum free light chains predict cardiovascular events in type 2 diabetes

Bellary, Srikanth; Faint, Jeffrey M.; Assi, Lakhvir K.; Hutchison, Colin A.; Harding, Stephen J.; Raymond, Neil T. and Barnett, Anthony H. (2014). Elevated serum free light chains predict cardiovascular events in type 2 diabetes. Diabetes Care, 37 (7), pp. 2028-2030.


OBJECTIVE: Elevated polyclonal serum immunoglobulin free light chains (FLCs; combined FLCκ+FLCλ [cFLC]) are associated with adverse clinical outcomes and increased mortality; we investigated cFLC and cardiovascular disease (CVD) events in type 2 diabetes. RESEARCH DESIGN AND METHODS: In a cohort study of 352 south Asian patients with type 2 diabetes, serum cFLC, high-sensitivity C-reactive protein (hsCRP), and standard biochemistry were measured. CVD events over 2 years were recorded and assessed usingmultiple logistic regression. RESULTS: cFLC levels were elevated significantly in 29 of 352 (8%) patients with CVD events during 2 years of follow-up (50.7 vs. 42.8mg/L; P = 0.004). Inmultivariate analysis, elevated cFLC (>57.2 mg/L) was associated with CVD outcomes (odds ratio 3.3 [95% CI 1.3-8.2]; P = 0.012) and remained significant after adjusting for age, albumin-to-creatinine ratio, diabetes duration, or treatment. CONCLUSIONS: cFLC elevation is a novel marker for CVD outcomes in type 2 diabetes that warrants further investigation. © 2014 by the American Diabetes Association.

Publication DOI: https://doi.org/10.2337/dc13-2227
Divisions: Life & Health Sciences > Biosciences
Additional Information: © 2014 by the American Diabetes Association.
Uncontrolled Keywords: Internal Medicine,Endocrinology, Diabetes and Metabolism,Advanced and Specialised Nursing,Medicine(all)
Published Date: 2014-07


Full text not available from this repository.

Export / Share Citation


Additional statistics for this record